Literature DB >> 12626776

Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells.

Anna C McDonnel1, Edward A Van Kirk, Dale D Isaak, William J Murdoch.   

Abstract

The lethality of common (surface) epithelial ovarian cancer is contingent on its metastatic capacity. Dissemination of the neoplasia throughout the abdominal cavity has been associated with secretion of proteolytic enzymes from vesicles shed by ovarian cancer cells. We report that the lipophilic steroid hormone progesterone decreases the fluid dynamics of plasma membranes of human SKOV-3 adenocarcinoma cells. The decrease in membrane fluidity was related to an inhibition in vitro of exocytotic vesicle release, cellular invasiveness into Matrigel, and colony formation in three-dimensional collagen matrix. Tumorigenesis was suppressed by progesterone in immunocompromised nude mice inoculated intraperitoneally with SKOV-3 cells. Progestins could therefore be of benefit in the prevention and(or) treatment of early-stage ovarian carcinomatosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626776     DOI: 10.1177/153537020322800310

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  15 in total

1.  Membrane fluidity, invasiveness and dynamic phenotype of metastatic prostate cancer cells after treatment with soy isoflavones.

Authors:  Vladimir Ajdžanović; Marija Mojić; Danijela Maksimović-Ivanić; Mirna Bulatović; Sanja Mijatović; Verica Milošević; Ivan Spasojević
Journal:  J Membr Biol       Date:  2013-02-16       Impact factor: 1.843

2.  Progesterone is essential for maintenance and growth of uterine leiomyoma.

Authors:  Hiroshi Ishikawa; Kazutomo Ishi; Vanida Ann Serna; Rafael Kakazu; Serdar E Bulun; Takeshi Kurita
Journal:  Endocrinology       Date:  2010-04-07       Impact factor: 4.736

3.  Inhibition of stearoylCoA desaturase activity blocks cell cycle progression and induces programmed cell death in lung cancer cells.

Authors:  Daniel Hess; Jeffrey W Chisholm; R Ariel Igal
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

4.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

5.  Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts.

Authors:  William J Murdoch; Edward A Van Kirk; Dale D Isaak; Youqing Shen
Journal:  Gynecol Oncol       Date:  2008-05-20       Impact factor: 5.482

6.  Ovarian morphometrics in TP53-deficient mice.

Authors:  Brenda M Alexander; Edward A Van Kirk; Leann M A Naughton; William J Murdoch
Journal:  Anat Rec (Hoboken)       Date:  2007-01       Impact factor: 2.064

7.  Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.

Authors:  Pengjun Zhang; Chuanxin Wang; Liming Cheng; Peng Zhang; Lin Guo; Wanli Liu; Zhongying Zhang; Yanchun Huang; Qishui Ou; Xinyu Wen; Yaping Tian
Journal:  Tumour Biol       Date:  2015-09-09

8.  Detection and analysis of multiple biomarkers in ovarian cancer: clinical significance in diagnosis, treatment, and prognosis evaluation.

Authors:  Rui Ji; Yong Li; Chenyun He; Xinghua Zhu; Aiqin He; Yunyan Lu
Journal:  Gland Surg       Date:  2020-12

9.  Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.

Authors:  Cathy B Wilcox; Grace O Feddes; Joan E Willett-Brozick; Lih-Ching Hsu; Julie A DeLoia; Bora E Baysal
Journal:  BMC Cancer       Date:  2007-12-11       Impact factor: 4.430

Review 10.  Estrogen, progesterone and epithelial ovarian cancer.

Authors:  Shuk-Mei Ho
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.